Circulating Tumor Cells Market Growth Trajectory Through 2024-2033

Spread the love

The Circulating Tumor Cells by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Circulating Tumor Cells Market:

https://www.thebusinessresearchcompany.com/report/circulating-tumor-cells-global-market-report

According to The Business Research Company’s Circulating Tumor Cells, The circulating tumor cells market size has grown rapidly in recent years. It will grow from $10.79 billion in 2023 to $12.21 billion in 2024 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to cancer incidence and prevalence, clinical utility in cancer staging, emergence of liquid biopsy, patient demand for minimally invasive tests, regulatory support for liquid biopsies, focus on early cancer detection..

The circulating tumor cells market size is expected to see rapid growth in the next few years. It will grow to $19.45 billion in 2028 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to point-of-care ctc testing, adoption of microfluidics, focus on rare cancer types, standardization of ctc assays, expansion of ctc-based clinical trials, economic and emerging market growth.. Major trends in the forecast period include innovations in ctc isolation techniques, government funding for ctc research, advancements in ctc detection technologies, liquid biopsy for cancer monitorin, integration with single-cell analysis, technological convergence with artificial intelligence (ai)..

The growing incidence of cancer is expected to propel the circulating tumor cells market growth going forward. Cancer refers to a disease in which a few body cells grow uncontrollably and spread to other parts. Circulating tumor cells are used to help in the early detection and diagnosis of cancer, and thus growing incidence of cancer propels the growth of the circulating tumor cells market For instance, in January 2023, according to reports shared by the American Cancer Society Inc., a US-based voluntary health organization, by 2021, 1.9 million new cancer cases will be diagnosed and 608,570 cancer deaths. Therefore, the growing incidence of cancer is driving the growth of the circulating tumor cells market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=8950&type=smp

The circulating tumor cells market covered in this report is segmented –

1) By Product: Kits And Reagents, Blood Collection Tubes, Devices Or Systems

2) By Technology: CTC Enrichment, CTC Detection, CTC Analysis

3) By Specimen: Blood, Bone Marrow, Other Body Fluids

4) By Application: Clinical Or Liquid Biopsy, Research

Product innovations are a key trend gaining popularity in the circulating tumor cells market. Major companies operating in the circulating tumor cells market are focused on developing innovative products to strengthen their position in the market. For instance, in February 2021, Menarini Silicon Biosystems, an Italy-based company operating in liquid biopsy and single-cell technologies, launched the new CellMag CTC Epithelial Cell kit. The kit uses ferrofluid technology to streamline the manual immuno-magnetic enrichment and staining of rare CTCs (circulating tumor cells). It is a cost-effective and simple protocol for liquid biopsy labs by allowing standardization of sample preparation.

The circulating tumor cells market report table of contents includes: